Steris Plc (NYSE:STE) insider Kathleen Bardwell sold 1,962 shares of Steris Plc stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $68.78, for a total transaction of $134,946.36. Following the completion of the sale, the insider now owns 16,538 shares of the company’s stock, valued at approximately $1,137,483.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Steris Plc (NYSE:STE) traded up 0.39% during mid-day trading on Wednesday, reaching $70.06. 407,244 shares of the company traded hands. The stock has a market capitalization of $5.97 billion, a price-to-earnings ratio of 35.37 and a beta of 1.27. Steris Plc has a 12-month low of $61.38 and a 12-month high of $74.63. The company’s 50-day moving average is $68.02 and its 200-day moving average is $69.22.
Steris Plc (NYSE:STE) last released its quarterly earnings data on Wednesday, November 2nd. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by $0.01. The company had revenue of $646.40 million for the quarter, compared to analysts’ expectations of $670.24 million. Steris Plc had a net margin of 6.41% and a return on equity of 9.89%. The business’s revenue for the quarter was up 31.9% compared to the same quarter last year. During the same period last year, the company posted $0.83 EPS. Equities analysts predict that Steris Plc will post $3.89 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 21st. Stockholders of record on Wednesday, November 23rd were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date was Monday, November 21st. Steris Plc’s dividend payout ratio (DPR) is presently 57.14%.
Several analysts have recently weighed in on STE shares. Zacks Investment Research upgraded shares of Steris Plc from a “sell” rating to a “hold” rating in a research note on Thursday, September 29th. Goldman Sachs Group, Inc. (The) started coverage on shares of Steris Plc in a research note on Wednesday, November 30th. They issued a “neutral” rating and a $71.00 price objective for the company. Finally, JMP Securities reiterated a “buy” rating on shares of Steris Plc in a research note on Friday, November 4th.
Several hedge funds have recently added to or reduced their stakes in the stock. Janus Capital Management LLC raised its stake in Steris Plc by 28.7% in the second quarter. Janus Capital Management LLC now owns 5,022,412 shares of the company’s stock worth $345,288,000 after buying an additional 1,120,438 shares during the period. American Century Companies Inc. raised its stake in Steris Plc by 870.8% in the second quarter. American Century Companies Inc. now owns 1,208,491 shares of the company’s stock worth $83,084,000 after buying an additional 1,084,007 shares during the period. Credit Suisse AG raised its stake in Steris Plc by 251.4% in the second quarter. Credit Suisse AG now owns 631,374 shares of the company’s stock worth $43,408,000 after buying an additional 451,699 shares during the period. Champlain Investment Partners LLC raised its stake in Steris Plc by 92.6% in the second quarter. Champlain Investment Partners LLC now owns 898,485 shares of the company’s stock worth $61,771,000 after buying an additional 431,945 shares during the period. Finally, Victory Capital Management Inc. bought a new stake in Steris Plc during the third quarter worth $27,646,000. 91.45% of the stock is owned by hedge funds and other institutional investors.
About Steris Plc
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.